A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Gedatolisib (Primary) ; Hydroxychloroquine
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLACIER
- 18 Nov 2019 Status changed from suspended to withdrawn prior to enrolment.
- 18 Nov 2019 Planned End Date changed from 1 Dec 2023 to 12 Nov 2019.
- 18 Nov 2019 Planned primary completion date changed from 1 Feb 2023 to 30 Aug 2019.